Lantern Pharma Creates Open-Medicine AI As Separate Entity
Lantern Pharma Inc. (Nasdaq: LTRN), a clinical-stage AI-driven precision oncology company, today announced the formal creation of Open-Medicine AI (OMAI) and the execution of commercial licensing agreements between OMAI
Lantern Pharma split off a new AI company called Open-Medicine AI and signed deals to use its technology. When companies create new separate businesses, it can mean they're trying new things, but watch to see if it helps them make money or just spreads focus too thin.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.